{'fraction_non_alphanumeric': 0.027538726333907058, 'fraction_numerical': 0.0, 'mean_word_length': 5.286486486486487, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic Targets in Breast Cancer Stem Cells

Breast cancer stem cells (BCSCs) constitute a subpopulation of tumor cells with self-renewal capability, expression of stem cell-like markers, and increased tumorigenicity in vivo. Clinical evidence has shown that BCSCs play a major role in the initiation, maintenance, and outcome of breast tumors. Therefore, BCSCs have been identified as ideal targets for the development of new therapies. Such therapies must consider the phenotypical differences between BCSCs cells, non-stem tumor cells, and normal cells. This review summarizes different strategies for BCSCs eradication that have been employed in preclinical assays, including: i) targeting proteins differentially expressed such as surface markers, transporters, or enzymes; ii) inhibiting self-renewal pathways; and iii) blocking the interaction of the BCSCs with their niche. These approaches may become the basis for the generation of effective and clinically applicable therapies that prevent disease relapse, metastasis, and enhance patient survival. Journal of Molecular Biomarkers & Diagnosis J o u r n a l o f M ole cul ar iorkers & iag n o s i s